| CatalogCode: | | NB110-57021 |
| ProductName: | | ErB2/HER2 Antibody |
| Product Description: | | Rabbit Monoclonal anti-ErB2/HER2 (SP) |
| Clone: | | SP |
| Clonality: | | Monoclonal |
| Specificity: | | A recombinant protein encoding extracellular domain of human ErbB2/HER2. |
| CrossReactivity: | | Reacts in human. Not tested in other species. |
| Packaging: | | 0.1 ml Rabbit ascites. |
| Uses: | | IHC: 1:100 |
| Background: | | ErbB2/HER2 is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of ErbB2 can be activated without ligand if it is overexpressed, and by association with other ErbB proteins (2). Overexpression of ErbB2 is detected in almost 40% of human breast cancers (3). Binding of c-Cbl ubiquitin ligase to Tyr1112 of ErbB2 leads to poly-ubiquitination of ErbB2 and enhances its degradation (4). ErbB2 is one of the major targets for the treatment of breast cancer and other carcinomas. |
| Storage: | | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Host_Name: | | Rabbit |
| Buffer: | | Tissue culture supernatant with 0.05% BSA. |
| ListPrice: | | 325 |
| AppSummary: | | IHC |
| SpeciesSummary: | | Hu |
| ALTnames: | | anti-C erbB 2 antibody, anti-C-erbB2 antibody, anti-CD340 antibody, anti-CerbB2 antibody, anti-Erb B2 antibody, anti-erbb2 antibody, anti-HER 2 antibody, anti-HER 2/neu antibody, anti-HER2 antibody, anti-Her2/neu antibody, anti-Herstatin antibody, anti-MLN 19 antibody, anti-MLN19 antibody, anti-NEU antibody, anti-NEU Proto Oncogene antibody, anti-Neuro Glioblastoma Derived Oncogene Homolog antibody, anti-NGL antibody, anti-p185 ErbB2 antibody, anti-p185erbB2 antibody, anti-Receptor Protein Tyrosine Kinase ErbB2 Precursor antibody, anti-Receptor tyrosine protein kinase erbB 2 antibody, anti-TKR1 antibody, anti-Tyrosine kinase type cell surface receptor HER2 antibody, anti-v erb b2 erythroblastic leukemia viral oncogene homolog 2 neuro/glioblastoma derived oncogene homolog (avian) antibody |
| PackageSize: | | 0.1 ml |
| GeneralRef: | | 1. Muthuswamy, S. K., et al. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol. 19: 6845-6857 (1999). 2. Qian, X., et al. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91: 1500-1504 (1994). 3. Dittadi, R. and M. Gion. More about: prognostic importance of low c-erbB2 expression in breast tumors. J. Natl. Cancer Inst. 92: 1443-1444 (2000). 4. Klapper, L. N., et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60: 3384-3388 (2000). |
| more information: | | company product webpage |
|